PFIZER - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 3.8
✅ Positive
Pfizer exhibits robust profit growth evidenced by increasing quarterly earnings and a strong Return on Capital Employed (ROCE). The company's conservative debt levels further enhance its financial stability, complemented by a reasonable dividend yield.
⚠️ Limitation
A high P/E ratio suggests the stock is trading at a premium relative to its peers, potentially indicating overvaluation and susceptibility to market fluctuations. The PEG ratio of 3.55 is notably above 1, suggesting that earnings growth may not fully justify the current valuation.
📉 Company Negative News
Recent news indicates a slight price decrease (-0.27%) for Pfizer shares, alongside concerns about its valuation highlighted by marketsmojo.com. Additionally, the declaration of ₹75 dividend per share doesn't fundamentally alter the long-term investment thesis given the stock’s premium multiple.
📈 Company Positive News
None found.
🏭 Industry
The pharmaceutical industry is characterized by substantial R&D investment and patent protection driving innovation. Companies like Pfizer operate within a highly regulated environment and benefit from aging populations driving demand for healthcare products, although competition remains intense.
🧾 Conclusion
Given the current price of 4,825 ₹, an entry zone between 4,500 ₹ and 4,700 ₹ represents an undervalued opportunity considering the company’s strong profitability and low debt levels. For long-term holding guidance, investors should focus on key milestones such as successful drug approvals and expansion into emerging markets; maintain a position for at least 3-5 years, closely monitoring industry trends and competitor activity to refine the outlook. The stock appears reasonably valued at present but is sensitive to clinical trial results and patent expiry risks.